Socioeconomic Disparities in Mortality among Women with Incident Breast Cancer before and after Implementation of Medicare Part D

Medical Care

Volumn 55, Issue 5, 2017, Pages 463-469

  Nattinger, Ann B ^a   Wozniak, Erica M ^a   McGinley, Emily L ^a   Li, Jianing ^a,b   Laud, Purushottam ^a   Pezzin, Liliana E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

breast cancer; medicare; mortality; socioeconomic factors

Indexed keywords

AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; EARLY CANCER; FEMALE; HIGHEST INCOME GROUP; HUMAN; INCOME; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; PRIORITY JOURNAL; SOCIAL STATUS; BREAST NEOPLASMS; ETHNIC GROUP; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; MIDDLE AGED; MORTALITY; POVERTY; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION;

AGED; BREAST NEOPLASMS; ETHNIC GROUPS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MEDICARE PART D; MIDDLE AGED; POVERTY; SOCIAL CLASS; UNITED STATES;

EID: 85007453737     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000685     Document Type: Article

References (24)

1. Harper S, Lynch J, Meersman SC, et al. Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev. 2009;18:121-131
2. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94: 490-496
3. Sprague BL, Trentham-Dietz A, Gangnon RE, et al. Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer. 2011;117:1542-1551
4. Hershman DL, Tsui J, Meyer J, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for earlystage breast cancer. J Natl Cancer Inst. 2014;106:1-9
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351: 1451-1467
6. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509-518
7. Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Translation. Washington, DC: The National Academies Press; 2006. doi:10.17226/11468
8. Pezzin LE, O'Niel MB, Nattinger AB. The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med. 2009;24: 446-450
9. Yen TW, Czypinski LK, Sparapani RA, et al. Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer. 2011;117:398-405
10. Nattinger AB, Pezzin LE, McGinley EL, et al. Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations [published online February 3, 2015]. Springerplus. doi:10.1186/s40064-015-0827-8
11. Nattinger AB, Laud PW, Bajorunaite R, et al. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39:1733-1749
12. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139
13. American Cancer Society. Breast Cancer: Mammography Statistics 2015. http://m.cancer.org/research/infographicgallery/mammographystatistics. Accessed November 28, 2015
14. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2006. Atlanta, GA: American Cancer Society; 2006
15. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010
16. Schmidt C. What drives diffusion of new cancer therapies? J Natl Cancer Inst. 2015;107:2-3
17. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:1-25
18. Neuner JM, Kamaraju S, Charlson JA, et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare Part D. J Natl Cancer Inst. 2015;107:1-7
19. Abaluck J, Gruber J. Choice inconsistencies among the elderly: evidence from plan choice in the Medicare Part D program. Am Econ Rev. 2011;101:1180-1210
20. Duggan M, Healy P, Morton FS. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D. J Econ Perspect. 2008;22:69-92
21. Heiss F, McFadden D, Winter J. Who failed to enroll in Medicare Part D, and why? Early results". Health Aff. 2006;25:w344-w354
22. Yin W, Basu A, Zhang J, et al. The impact of the Medicare Part D prescription drug benefit on drug utilization and expenditures. Ann Intern Med. 2008;148:169-177
23. Schneeweiss S, Patrick AR, Pedan A, et al. The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff. 2009;28:305-316
24. Polinski JM, Kilabuk E, Schneeweiss S, et al. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc. 2010;58:1764-1779